Diabetes with hypertension medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 12: Line 12:
:*Low dose [[diuretics]]
:*Low dose [[diuretics]]


==Supportive trial data==
==Supportive Trial Data==


===Study name: LIFE study, 2002 <ref name="pmid11937179">{{cite journal| author=Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U et al.| title=Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. | journal=Lancet | year= 2002 | volume= 359 | issue= 9311 | pages= 1004-10 | pmid=11937179 | doi=10.1016/S0140-6736(02)08090-X | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11937179  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12418827 Review in: ACP J Club. 2002 Nov-Dec;137(3):87] </ref>===
===Study Name: LIFE Study, 2002 <ref name="pmid11937179">{{cite journal| author=Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U et al.| title=Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. | journal=Lancet | year= 2002 | volume= 359 | issue= 9311 | pages= 1004-10 | pmid=11937179 | doi=10.1016/S0140-6736(02)08090-X | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11937179  }}  [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12418827 Review in: ACP J Club. 2002 Nov-Dec;137(3):87] </ref>===
* '''Study design''': Double blinded, randomised, parallel-group trial
* '''Study design''': Double blinded, randomised, parallel-group trial
* '''Sample size''': 1195 patients with diabetes, hypertension, [[left ventricular hypertrophy]] (on electrocardiograms)
* '''Sample size''': 1195 patients with diabetes, hypertension, [[left ventricular hypertrophy]] (on electrocardiograms)
Line 21: Line 21:
* '''Study results''': Losartan was found to be more effective than atenolol in reducing composite endpoints like cardiovascular morbidity and all causes mortality in patients with hypertension, diabetes, and [[left-ventricular hypertrophy]].
* '''Study results''': Losartan was found to be more effective than atenolol in reducing composite endpoints like cardiovascular morbidity and all causes mortality in patients with hypertension, diabetes, and [[left-ventricular hypertrophy]].


===Study name: Candesartan and Lisinopril microalbuminuria (CALM) study, 2000 <ref name="pmid11110735">{{cite journal| author=Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al.| title=Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. | journal=BMJ | year= 2000 | volume= 321 | issue= 7274 | pages= 1440-4 | pmid=11110735 | doi= | pmc=PMC27545 | url= }} </ref>===
===Study Name: Candesartan and Lisinopril Microalbuminuria (CALM) Study, 2000 <ref name="pmid11110735">{{cite journal| author=Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al.| title=Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. | journal=BMJ | year= 2000 | volume= 321 | issue= 7274 | pages= 1440-4 | pmid=11110735 | doi= | pmc=PMC27545 | url= }} </ref>===


* '''Study design''': Double blinded,  prospective, randomised, parallel-group, multicenteric (4 countries, 37 centers) trial
* '''Study design''': Double blinded,  prospective, randomised, parallel-group, multicenteric (4 countries, 37 centers) trial
Line 33: Line 33:
* '''Study results''':  Candesartan was found to be as effective as lisinopril in reducing blood pressure and [[microalbuminuria]] in hypertensive type 2 diabetics. Combination treatment (Candesartan+lisinopril) was well tolerated and more effective in reducing blood pressure compared to either drugs alone.
* '''Study results''':  Candesartan was found to be as effective as lisinopril in reducing blood pressure and [[microalbuminuria]] in hypertensive type 2 diabetics. Combination treatment (Candesartan+lisinopril) was well tolerated and more effective in reducing blood pressure compared to either drugs alone.


===Study name: Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial, ('''[[FACET]]'''), 1998 <ref name="pmid9571349">{{cite journal| author=Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G et al.| title=Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. | journal=Diabetes Care | year= 1998 | volume= 21 | issue= 4 | pages= 597-603 | pmid=9571349 | doi= | pmc= | url= }} </ref>===
===Study Name: Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial, ('''[[FACET]]'''), 1998 <ref name="pmid9571349">{{cite journal| author=Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G et al.| title=Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. | journal=Diabetes Care | year= 1998 | volume= 21 | issue= 4 | pages= 597-603 | pmid=9571349 | doi= | pmc= | url= }} </ref>===
* '''Study design''': Open label, randomized trial
* '''Study design''': Open label, randomized trial
* '''Sample size''': 380 [[hypertension|hypertensive]] diabetics patient
* '''Sample size''': 380 [[hypertension|hypertensive]] diabetics patient

Revision as of 18:36, 8 February 2013

Diabetes mellitus Main page

Patient Information

Type 1
Type 2

Overview

Classification

Diabetes mellitus type 1
Diabetes mellitus type 2
Gestational diabetes

Differential Diagnosis

Complications

Screening

Diagnosis

Prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]; Cafer Zorkun, M.D., Ph.D. [3]

Overview

Hypertension is a common co-morbidity associated with patients of diabetes, especially type 2 diabetes. Co-existence of these conditions strongly predispose patients to both renal as well as cardiovascular (CV) injury. Diabetes is the most common cause of end-stage renal disease in the United States. The 1994 Working Group Report on Hypertension and Diabetes, has recommended the original blood pressure goals of less than 130/85 mmHg to preserve renal function and reduce cardiovascular events in these groups of patients.

Treatment

The preferred treatment of the diabetic with hypertension includes:

Supportive Trial Data

Study Name: LIFE Study, 2002 [1]

  • Study design: Double blinded, randomised, parallel-group trial
  • Sample size: 1195 patients with diabetes, hypertension, left ventricular hypertrophy (on electrocardiograms)
  • Study drugs: Losartan or Atenolol
  • Study period: 4 years
  • Study results: Losartan was found to be more effective than atenolol in reducing composite endpoints like cardiovascular morbidity and all causes mortality in patients with hypertension, diabetes, and left-ventricular hypertrophy.

Study Name: Candesartan and Lisinopril Microalbuminuria (CALM) Study, 2000 [2]

  • Study design: Double blinded, prospective, randomised, parallel-group, multicenteric (4 countries, 37 centers) trial
  • Sample size: 199 patients with diabetes & hypertension
  • Study drugs: Candesartan or lisinopril
  • Study period:
    • Placebo run in period-4 weeks
    • 12 weeks Candesartan or lisinopril
    • Followed by 12 weeks' monotherapy or combination treatment
  • Study question: Compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion , hypertension, and type 2 diabetes.
  • Study results: Candesartan was found to be as effective as lisinopril in reducing blood pressure and microalbuminuria in hypertensive type 2 diabetics. Combination treatment (Candesartan+lisinopril) was well tolerated and more effective in reducing blood pressure compared to either drugs alone.

Study Name: Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial, (FACET), 1998 [3]

References

  1. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U; et al. (2002). "Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol". Lancet. 359 (9311): 1004–10. doi:10.1016/S0140-6736(02)08090-X. PMID 11937179. Review in: ACP J Club. 2002 Nov-Dec;137(3):87
  2. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW; et al. (2000). "Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study". BMJ. 321 (7274): 1440–4. PMC 27545. PMID 11110735.
  3. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G; et al. (1998). "Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM". Diabetes Care. 21 (4): 597–603. PMID 9571349.

Template:WH Template:WS